The complete response letter, issued by the FDA, does not identify what deficiencies regulators found in ...

Seth Eisenberg, ASN, RN, OCN, BMTCN discussed the results of a real-world trial of Splashblocker, a toilet seat cover ...

The WOLVERINE meta-analysis reinforces the role of MDT in delaying disease progression in patients with oligometastatic ...

Evaluation of nemvaleukin for platinum-resistant ovarian cancer will be terminated based on OS data from an interim analysis ...

Debriefing after patient loss, supporting patients at the end of life, and finding outlets outside of work can help oncology nurses avoid burnout.

The FDA has approved neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab after radical cystectomy in MIBC.

Experts discuss how to manage fatigue, abdominal pain, and other treatment-related symptoms to maintain or improve quality of life for patients undergoing HER2-targeted therapy and share strategies ...

Experts discuss how to facilitate open communication among the patient, caregivers, and the multidisciplinary team to ensure comprehensive care and alignment on treatment goals.

Vepdegestrant (ARV-471) yielded a statistically significant and clinically meaningful improvement in progression-free ...

BC, OCN, explained that comprehensive disease and treatment education are essential to adherence for patients with breast ...

In myeloma treatment, acute CRS is a common but treatable AE associated with CAR T-cell therapy and bispecific antibodies, ...

Restaging cancer can be an unfamiliar space, but with more experience, APPs can rely less on MDs for guidance in such cases.